Abstracts tagged "prognostic factors"

Abstract Number: 203 • 2012 ACR/ARHP Annual Meeting
Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Hyemin Jeong¹, Eun-Jung Park¹, Jiwon Hwang¹, Ji Young Chai², Joong Kyong Ahn³, Eun-Mi Koh⁴ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ³Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea
Background/Purpose: To evaluate the clinical features and outcomes in patients with monoarthritis and to investigate predictive factors associated with the clinical course in terms of…
Abstract Number: 2140 • 2012 ACR/ARHP Annual Meeting
A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study
Paul Bird¹, David Nicholls², Julien P. de Jager³, Hedley Griffiths⁴, Lynden Roberts⁵, Kathleen Tymms⁶, Jane Zochling⁷, Mark H. Arnold⁸, Geoffrey O. Littlejohn⁹ and OPAL Consortium¹⁰, ¹Combined Rheumatology Practice, Sydney, Australia, ²Coast Joint Care, Maroochydore, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Barwon Rheumatology Service, Geelong, Australia, ⁵School of Medicine, James Cook University, Townsville, Australia, ⁶Canberra Rheumatology, Canberra, ACT, Australia, ⁷Menzies Research Institute Tasmania, Hobart, Australia, ⁸Orthopaedic Arthritis Spec Ctr, Level 2 The Gallery, Chatswood, Australia, ⁹Rheumatology, Monash Medical Center, Melbourne, Australia, ¹⁰Melbourne, Australia
Background/Purpose: Despite the conspicuous increase in available treatment for rheumatoid arthritis [RA], and the shift to early, more aggressive management, there is a paucity of…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].